Tessa Therapeutics To Host Scientific Session On CD30 CAR-T Targeting Of CD30+ Lymphomas At The SDCT-REMEDIS Cell Therapy Conference 2022
SINGAPORE, June 14 (Bernama-GLOBE NEWSWIRE) —Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022. Tessa’s scientific session will focus…

